Hospital Pharmacy - October 2020 - 305

305

Jamshed et al

Limitation
Some of the main limitations of this study are the following:
** This review only includes studies between 2000 and
2015, so studies published after 2015 are not part of
this review as this review was initially completed in
2015 and thus limits the scope.
** Second, studies published in PubMed database and in
English language are included, which limits the range
of this review.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Sana Shamim

https://orcid.org/0000-0001-8630-8644

References
1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the
epidemiology of gastroesophageal reflux disease: a systematic
review. Gut. 2014;63:871-880.
2. Boeckxstaens G, El-Serag HB, Smout AJ, Kahrilas PJ.
Symptomatic reflux disease: the present, the past and the future.
Gut. 2014;63:1185-1193. doi:10.1136/gutjnl-2013-306393.
3. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran
M, Bazzoli F, Ford AC. Global prevalence of, and risk factors
for, gastro-esophageal reflux symptoms: a meta-analysis. Gut.
2017;67:430-440. doi:10.1136/gutjnl-2016-313589.
4. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME.
Short-term treatment with proton pump inhibitors, H2-receptor
antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Cochrane Database Syst Rev. 2013;(5):CD002095.
5. Sandhu DS, Fass R. Current trends in the management of
gastroesophageal reflux disease. Gut Liver. 2017;12:7-16.
doi:10.5009/gnl16615.
6. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal
disease in the United States: 2012 update. Gastroenterology.
2012;143(5):1179-1187.
7. Gerson LB, Robbins AS, Garber A, Hornberger J,
Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux
disease. Am J Gastroenterol. 2000;95(2):395-407.
8. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA.
Effectiveness and costs of omeprazole vs ranitidine for
treatment of symptomatic gastroesophageal reflux disease

in primary care clinics in West Virginia. Arch Family Med.
2000;9(7):624-630.
9. Ofman JJ, Yamashita BD, Siddique RM, Larson LR, William
MK. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Management Care. 2000;6(8):905-916.
10. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux
disease without oesophagitis: comparison of on-demand
esomeprazole with conventional omeprazole strategies.
Pharmacoeconomics. 2002;20(4):267-277.
11. Goeree R, O'Brien BJ, Blackhouse G, Marshall J, Briggs A,
Lad R. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health. 2002;5(4):312-328.
12. Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons
D. Preventing non-steroidal anti-inflammatory drug-induced
gastrointestinal toxicity: are older strategies more cost-effective
in the general population? Rheumatology. 2006;45(5):606-613.
13. Szucs T, Thalmann C, Michetti P, Beglinger C. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole
on-demand treatment or esomeprazole continuous treatment:
an open, randomized, multicenter study in Switzerland. Value
Health. 2009;12(2):273-281.
14. Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K. Proton pump
inhibitors: potential cost reductions by applying prescribing
guidelines. BMC Health Serv Res. 2012;12(1):408.
15. de Groot NL, Spiegel BM, van Haalen HG, de Wit NJ,

Siersema PD, van Oijen MG. Gastroprotective strategies in
chronic NSAID users: a cost-effectiveness analysis comparing
single-tablet formulations with individual components. Value
Health. 2013;16(5):769-777.
16. Funk LM, Zhang JY, Drosdeck JM, Melvin WS, Walker JP,
Perry KA. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux
disease. Surg. 2015;157(1):126-136.
17. Van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME.
Short-term treatment with proton pump inhibitors, H2-receptor
antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Cochrane Database Syst Rev. 2010;11:CD002095.
18. MacLaren R, Campbell J. Cost-effectiveness of histamine

receptor-2 antagonist versus proton pump inhibitor for stress
ulcer prophylaxis in critically ill patients. Critical Care Med.
2014;42(4):809-815.
19. Ponce J, Argüello L, Bastida G, Ponce M, Ortiz V, Garrigues
V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Dig Dis Sci. 2004;49(6):931-936.
20. Bayerdörffer E, Bigard MA, Weiss W, et al. Randomized,
multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with nonerosive gastroesophageal reflux disease. BMC Gastroenterol.
2016;16(1):48.

https://www.orcid.org/0000-0001-8630-8644

Hospital Pharmacy - October 2020

Table of Contents for the Digital Edition of Hospital Pharmacy - October 2020